POOLBEG PHARMA PLC (POLB) — POLB 001 Phase 2a Trial Update

Investor webinar replay

Replay transcript excerpt

Good afternoon, ladies and gentlemen. Welcome to the POLBEG PHARMA PLC Investor Presentation. The company may not be in a position to answer every question received during the meeting itself. However, the company can review your questions submitted today and will publish those responses where it's appropriate to do so. Before we begin, we'd like to submit the following poll. I'm sure the company would be most grateful for your participation. I'd now like to hand over to the presenting team from POLBEG, Jeremy, Liam. Good afternoon. Good afternoon. Good afternoon, and thank you for that introduction. Good afternoon, everybody, and thank you for joining us for this presentation today. The plan of action is Liam and I will go through a set of slides, probably take you about twenty five, thirty minutes or so to give you a background and context to our kind of recent activities, recent news, and obviously future planning. And then, we'll have ten or fifteen minutes or so for, for q and a at the end. So, as stated, if you wanna ask questions, please, drop them in. So we'll start off, usual legal disclaimer, and then I just wanna ground everybody, maybe new attendees, to pull back who we are, and I think why it's an exciting company to invest in and, our plans for the future. So we are a clinical stage biopharmaceutical company with a core focus on transforming the cancer immunotherapy field. We'll talk about that in-depth in detail later on with our POLB zero zero one clinical trial that's upcoming. And we're also developing an oral patient friendly obesity treatment. So we're tackling two very large markets with significant unmet medical needs. The investment case in the middle of this slide here, we have a very experienced team with a proven track record of both clinical...